Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Reinholz

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Epidemiology and Infection|February 10, 2023
The effectiveness of an extra-curricular lecture for STI prevention and sexual educationM Reinholz, T Nellessen, E Wei, et al.
Oncogene|February 12, 2008
Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenograftsA B D'Assoro, R Busby, I D Acu, et al.
Letters in Applied Microbiology|May 19, 2022
In vitro and in vivo detection of microbial gene expression in bioactivated scaffolds seeded with cyanobacteriaL B Leibrock, D M Hofmann, B Fuchs, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|August 7, 2009
Transforming growth factor-beta1 modulates insulin-like growth factor binding protein-4 expression and proteolysis in cultured periosteal explantsCarlos Gonzalez, Kiem G Auw Yang, Joseph H Schwab, et al.
Journal of the National Cancer Institute|December 6, 2011
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteriaEdith A Perez, Amylou C Dueck, Ann E McCullough, et al.
British Journal of Cancer|August 14, 2014
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trialH Cheng, K Ballman, M Vassilakopoulou, et al.
Breast Cancer Research and Treatment|January 8, 2014
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring studyAnn E McCullough, Patrizia Dell'orto, Monica M Reinholz, et al.
Molecular Cancer Therapeutics|April 17, 2008
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomyJudith A Gilbert, Matthew P Goetz, Carol A Reynolds, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437Monica M Reinholz, Kathleen A Kitzmann, Kathleen Tenner, et al.
Cancer|June 8, 2013
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831Alvaro Moreno-Aspitia, David W Hillman, Stephen H Dyar, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Epidemiology and Infection|February 10, 2023
The effectiveness of an extra-curricular lecture for STI prevention and sexual educationM Reinholz, T Nellessen, E Wei, et al.
Oncogene|February 12, 2008
Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenograftsA B D'Assoro, R Busby, I D Acu, et al.
Letters in Applied Microbiology|May 19, 2022
In vitro and in vivo detection of microbial gene expression in bioactivated scaffolds seeded with cyanobacteriaL B Leibrock, D M Hofmann, B Fuchs, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|August 7, 2009
Transforming growth factor-beta1 modulates insulin-like growth factor binding protein-4 expression and proteolysis in cultured periosteal explantsCarlos Gonzalez, Kiem G Auw Yang, Joseph H Schwab, et al.
Journal of the National Cancer Institute|December 6, 2011
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteriaEdith A Perez, Amylou C Dueck, Ann E McCullough, et al.
British Journal of Cancer|August 14, 2014
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trialH Cheng, K Ballman, M Vassilakopoulou, et al.
Breast Cancer Research and Treatment|January 8, 2014
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring studyAnn E McCullough, Patrizia Dell'orto, Monica M Reinholz, et al.
Molecular Cancer Therapeutics|April 17, 2008
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomyJudith A Gilbert, Matthew P Goetz, Carol A Reynolds, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437Monica M Reinholz, Kathleen A Kitzmann, Kathleen Tenner, et al.
Cancer|June 8, 2013
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831Alvaro Moreno-Aspitia, David W Hillman, Stephen H Dyar, et al.
Pageof 6